Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 1,834 Shares

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 1,834 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $65.54, for a total value of $120,200.36. Following the sale, the chief accounting officer directly owned 44,061 shares of the company’s stock, valued at approximately $2,887,757.94. This represents a 4.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Tempus AI Price Performance

TEM traded down $3.40 during trading on Thursday, hitting $65.69. The stock had a trading volume of 7,149,431 shares, compared to its average volume of 6,352,496. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. Tempus AI, Inc. has a twelve month low of $31.36 and a twelve month high of $104.32. The company’s 50-day moving average price is $83.96 and its 200 day moving average price is $71.87.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The firm had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. During the same period in the prior year, the company posted ($0.46) earnings per share. The firm’s revenue for the quarter was up 84.7% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on TEM shares. Morgan Stanley boosted their target price on shares of Tempus AI from $68.00 to $80.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Guggenheim increased their target price on shares of Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a report on Friday, September 26th. Cowen lowered Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Piper Sandler dropped their price objective on Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Finally, BTIG Research reaffirmed a “buy” rating and set a $96.00 price objective on shares of Tempus AI in a report on Wednesday, November 5th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Tempus AI has an average rating of “Hold” and an average target price of $80.00.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cranbrook Wealth Management LLC acquired a new position in shares of Tempus AI in the third quarter worth $25,000. JPL Wealth Management LLC acquired a new position in Tempus AI in the 3rd quarter valued at about $26,000. GAMMA Investing LLC purchased a new position in Tempus AI in the 3rd quarter valued at about $28,000. Concord Wealth Partners boosted its stake in shares of Tempus AI by 308.0% during the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after buying an additional 450 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.